☆ 4.7 Letter

The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series

ANNALS OF THE RHEUMATIC DISEASES (2021)

Related references

Note: Only part of the references are listed.
Article Dermatology

Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study

Hsien-Yi Chiu et al.

Summary: This study found that patients with psoriasis receiving biologics are at risk of HBV and HCV reactivations, especially those who are HBsAg and HBeAg positive and undergoing tumor necrosis factor-alpha-inhibitor therapy. Antiviral prophylaxis was effective in reducing the risk of HBV reactivation. No predictors were significantly associated with HCV reactivation.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection
Review Immunology

Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics

Ying-Ming Chiu et al.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2020)

Add to Collection
Article Gastroenterology & Hepatology

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Norah A. Terrault et al.

HEPATOLOGY (2018)

Add to Collection
Article Gastroenterology & Hepatology

Role of Surface Antibody in Hepatitis B Reactivation in Patients With Resolved Infection and Hematologic Malignancy: A Meta-analysis

Sonali Paul et al.

HEPATOLOGY (2017)

Add to Collection
Article Gastroenterology & Hepatology

American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy

Robert P. Perrillo et al.

GASTROENTEROLOGY (2015)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.